SHL Telemedicine Ltd
SHLTN
ISIN IL0010855885 / Valor 1128957
SHL Telemedicine Ltd
UMushroom community rating:
About company
SHL Telemedicine Ltd specializes in the development and provision of advanced telemedicine solutions and services, focusing on the diagnosis and monitoring of heart conditions and various chronic diseases. The company is recognized as a leading provider of telemedicine in Israel and Germany, offering 24/7 telemedicine centers in these countries, with services extending globally through cloud technology. SHL Telemedicine facilitates around 3 million medical interactions annually and is noted for its innovation in personal use hospital-grade mobile 12-lead ECG devices, which have received FDA clearance. The company's product portfolio includes a range of telemedicine devices designed for personal use, enabling real-time transmission of critical medical data, such as ECG and blood pressure readings, to SHL's medical monitoring centers for immediate evaluation. SHL Telemedicine's operations leverage artificial intelligence and big data technologies, and the company collaborates with leading healthcare industry partners, including the Mayo Clinic, to enhance its service offerings and expand its market presence, particularly in Germany and the USA.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.11.2025):
SHL Telemedicine Ltd reported its Half-Year 2024 financial results, showcasing modest revenue declines with slight operational improvements. In this period, total revenues reached USD 27.9m, down 2% from H1 2023, while adjusted EBITDA improved to USD 0.5m compared to USD 0.3m in the prior year. The report also highlights key leadership appointments and operational cost reductions, particularly in Germany and the US, underscoring SHL Telemedicine’s commitment to strategic growth in diverse markets.
Revenue Performance
Total revenues were USD 27.9m, with stable performance in Israel (USD 20.9m) and a slight decline in Germany (USD 6.6m) compared to H1 2023, complemented by the presentation of Rest of World results at USD 0.4m.
Operational Efficiency
Adjusted EBITDA increased to USD 0.5m from USD 0.3m in H1 2023, driven by operational improvements including a 4% boost in adjusted EBITDA in Israel and a USD 1m reduction in operational losses in Germany.
Financial Income and Net Loss
Financial income, net decreased to USD 0.5m from USD 3.0m due to the absence of a USD 1.8m investors options income recognized previously, contributing to a widened net loss of USD 3.9m from USD 2.2m in H1 2023.
Strategic Investments and Leadership Changes
The company expanded its investments in US direct-to-consumer operations by USD 0.7m and made significant leadership appointments, including the new chairman Dr. Itamar Offer and CEO Mr. David Arnon, to enhance strategic direction and operational execution.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
28 M
Market cap (USD)
24,796
Daily traded volume (Shares)
2.67 / 2.43
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Janin Sägesser
EQUITIES OF THE SAME SECTOR
